<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03093116</url>
  </required_header>
  <id_info>
    <org_study_id>TPX-0005-01</org_study_id>
    <nct_id>NCT03093116</nct_id>
  </id_info>
  <brief_title>A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements</brief_title>
  <acronym>TRIDENT-1</acronym>
  <official_title>A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turning Point Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turning Point Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the
      maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose
      (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an
      ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.

      Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction.

      Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded
      Independent Central Review (BICR) of repotrectinib in each subject population expansion
      cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene
      rearrangement. The secondary objective will include the duration of response (DOR), time to
      response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit
      rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a
      ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Phase 2, study subjects will be enrolled into 6 distinct expansion (EXP) cohorts:

        -  EXP-1: ROS1 TKI-naïve ROS1+ NSCLC. Up to one prior line of chemotherapy OR immunotherapy
           is allowed

        -  EXP-2: 1 Prior ROS1 TKI AND 1 Platinum-based Chemotherapy ROS1+ NSCLC. Disease
           progression, or intolerant to one prior line of a ROS1 TKI. Must have received one prior
           line of platinum based chemotherapy OR one prior line of platinum based chemotherapy in
           combination with immunotherapy before or after a ROS1 TKI

        -  EXP-3: 2 Prior ROS1 TKIs AND 1 Platinum-based Chemotherapy ROS1+ NSCLC. Disease
           progression, or intolerant to 2 prior lines of a ROS1 TKI treatment. Must have received
           one prior line of platinum based chemotherapy OR one prior line of platinum based
           chemotherapy in combination with immunotherapy before or after a ROS1 TKI

        -  EXP-4: 1 Prior ROS1 TKI and NO Chemotherapy or Immunotherapy ROS1+ NSCLC. Disease
           progression or intolerant to one prior line of a ROS1 TKI. No prior lines of
           chemotherapy or immunotherapy are allowed.

        -  EXP-5: TRK TKI-naïve NTRK+ solid tumors. Any number of prior lines of chemo or
           immunotherapy is allowed.

        -  EXP-6: TRK TKI-pretreated NTRK+ solid tumors. Disease progression, or intolerant to 1 or
           2 prior TRK TKIs. Any number of prior lines of chemo- or immunotherapy are allowed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2017</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicities (DLTs) (Phase 1)</measure>
    <time_frame>Within 28 days of the first repotrectinib dose</time_frame>
    <description>Define the dose limiting toxicities (DLTs) (Phase 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D) (Phase 1)</measure>
    <time_frame>Within 28 days of the last patient dosed in escalation</time_frame>
    <description>To determine the RP2D (Phase 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (ORR) Phase 2</measure>
    <time_frame>Two to three years after first dose of repotrectinib dose</time_frame>
    <description>To determine the confirmed ORR of repotrectinib (TPX-0005) as assessed by Blinded Independent Central Review (Phase 2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (CMAX) of repotrectinib (TPX-0005) (Phase 1)</measure>
    <time_frame>Up to 72 hours post dose</time_frame>
    <description>To determine the maximum plasma concentration (CMAX) of repotrectinib (TPX-0005)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration time curve (AUC) of repotrectinib (TPX-0005) (Phase 1)</measure>
    <time_frame>Up to 72 hours post dose</time_frame>
    <description>To determine the area under the plasma concentration time curve (AUC) of repotrectinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration time curve (AUC) of repotrectinib under different food intake conditions(TPX-0005) (Phase 1)</measure>
    <time_frame>Up to 72 hours post dose</time_frame>
    <description>To determine the area under the plasma concentration time curve (AUC) of repotrectinib under different food intake conditions(TPX-0005) (Phase 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (CMAX) of repotrectinib under different food intake conditions(TPX-0005) (Phase 1)</measure>
    <time_frame>Up to 72 hours post dose</time_frame>
    <description>To determine the maximum plasma concentration (CMAX) of repotrectinib under different food intake conditions(TPX-0005) (Phase 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration time curve (AUC) of midazolam(TPX-0005) (Phase 1)</measure>
    <time_frame>Up to 24 hours post dose</time_frame>
    <description>To determine the area under the plasma concentration time curve (AUC) of midazolam(TPX-0005) (Phase 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (CMAX) of midazolam(TPX-0005) (Phase 1)</measure>
    <time_frame>Up to 24 hours post dose</time_frame>
    <description>To determine the maximum plasma concentration (CMAX) of midazolam(TPX-0005) (Phase 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of repotrectinib following administration at RP2D (Phase 2)</measure>
    <time_frame>Pre dose and 4 hours post dose</time_frame>
    <description>To evaluate the plasma concentration of repotrectinib following administration at RP2D (Phase 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary objective response rate (ORR) (Phase 1)</measure>
    <time_frame>Approximately three years</time_frame>
    <description>To determine the preliminary objective response rate (ORR) by Blinded Independent Central Review (BICR) (Phase 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) (Phase 2)</measure>
    <time_frame>Approximately three years</time_frame>
    <description>To determine the DOR of repotrectinib (TPX-0005) (Phase 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR) (Phase 2)</measure>
    <time_frame>Approximately three years</time_frame>
    <description>To determine the CBR of repotrectinib (TPX-0005) (Phase 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) (Phase 2)</measure>
    <time_frame>Approximately three years</time_frame>
    <description>To determine the PFS (Phase 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) (Phase 2)</measure>
    <time_frame>Approximately three years</time_frame>
    <description>To determine the OS (Phase 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial objective response rate (Phase 2)</measure>
    <time_frame>Approximately three years</time_frame>
    <description>To determine the intracranial objective response rate (Phase 2)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Locally Advanced Solid Tumors</condition>
  <condition>Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Repotrectinib (TPX-0005)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1
Oral repotrectinib (TPX-0005):
Phase 1a dose escalation, Phase 1b food-effect sub-study, and Phase 1c dose escalation with food, and Midazolam drug-drug interaction sub-study.
Phase 2
Oral repotrectinib (TPX-0005): 6 distinct expansion cohorts
EXP-1: ROS1 TKI-naïve ROS1+ NSCLC
EXP-2: 1 Prior ROS1 TKI and 1 Platinum based chemo ROS1+ NSCLC
EXP-3: 2 Prior ROS1 TKIs and 1 Platinum based chemo ROS1+ NSCLC
EXP-4: 1 Prior ROS1 TKI ROS1+ NSCLC (No Chemo or IO)
EXP-5: TRK TKI-naïve NTRK+ solid tumors
EXP-6: TRK TKI-pretreated NTRK+ solid tumors</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral repotrectinib (TPX-0005)</intervention_name>
    <description>Oral repotrectinib (TPX-0005) capsules.</description>
    <arm_group_label>Repotrectinib (TPX-0005)</arm_group_label>
    <other_name>repotrectinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PHASE 1

        Key Inclusion Criteria:

          1. Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic
             solid tumor (including primary CNS tumors) (Stage IV, American Joint Committee on
             Cancer v.7) that harbors an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement by
             protocol specified tests.

          2. ECOG PS 0-1.

          3. Age ≥18 (or age ≥ 20 of age as required by local regulation).

          4. Capability to swallow capsules intact (without chewing, crushing, or opening).

          5. At least 1 measurable target lesion according to RECIST version 1.1. CNS-only
             measurable disease as defined by RECIST version 1.1 is allowed.

          6. Prior cytotoxic chemotherapy is allowed.

          7. Prior immunotherapy is allowed.

          8. Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer
             therapy to National Cancer Institute Common Terminology Criteria for Adverse Events
             (NCI CTCAE) Version 4.03 Grade less than or equal to 1.

          9. Patients with asymptomatic CNS metastases (treated or untreated) and/or asymptomatic
             leptomeningeal carcinomatosis are eligible to enroll if they satisfy the protocol
             specified criteria.

         10. Baseline laboratory values fulfilling the following requirements:Absolute neutrophils
             count (ANC) ≥1500/mm3 (1.5 × 109/L); Platelets (PLTs) ≥100,000/mm3 (100 × 109/L);
             Hemoglobin ≥ 9.0 g/dL transfusions are allowed; Serum creatinine or creatinine
             clearance Within normal limits or &gt; 40 mL/min; Total serum bilirubin &lt; 1.5 × ULN;
             Liver transaminases (ASTs/ALTs) &lt; 2.5 × ULN; &lt; 5 × ULN if liver metastases are present
             Alkaline phosphatase (ALP); &lt; 2.5 × ULN; &lt; 5 × ULN if liver and/or bone metastasis are
             present; Serum calcium, magnesium, and potassium Normal or CTCAE grade ≤ 1 with or
             without supplementation

         11. Life expectancy ≥ 3 months.

        PHASE 2 Key Inclusion Criteria

          1. Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic
             solid tumor (including primary CNS tumors) that harbors a ROS1, or NTRK1-3 gene
             fusion.

          2. Subject must have a documented ROS1 or NTRK1-3 gene fusion determined by tissue-based
             local testing using either:

               1. a next-generation sequencing (NGS) or quantitative polymerase chain reaction
                  (qPCR) test will be accepted to determine molecular eligibility.

                  • Adequate tumor tissue needs to be sent to the Sponsor designated central
                  diagnostic laboratory for retrospective confirmation by a central diagnostic
                  laboratory test selected by the Sponsor.

                  OR

               2. a fluorescence in situ hybridization (FISH) test AND prospective confirmation of
                  fusion status by a central diagnostic laboratory test selected by the Sponsor
                  PRIOR to enrollment will be accepted to determine molecular eligibility.

                    -  Adequate tumor tissue must be sent to the Sponsor designated central
                       diagnostic laboratory for prospective confirmation by a central diagnostic
                       laboratory test selected by the Sponsor PRIOR to enrollment.

          3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.

          4. Age ≥12 (or age ≥ 20 as required by local regulation).

          5. Willing and able to provide written institutional review board (IRB)/institutional
             ethics committee-approved Informed Consent or an Assent signed by a parent or legal
             guardian for subjects age 12 to 17.

          6. At least 1 measurable target lesion according to RECIST (v1.1) prospectively confirmed
             by Blinded Independent Central Radiology Review (BICR), selected by Sponsor, PRIOR to
             enrollment. Subjects with CNS-only measurable disease ≥10 mm as defined by RECIST
             (v1.1) are eligible.

          7. Subjects with advanced solid tumors harboring ROS1, NTRK1, NTRK2, or NTRK3
             rearrangement will be assigned into 6 distinct expansion (EXP) cohorts provided all
             inclusion and exclusion criteria are met.

             i. EXP-1: ROS1 TKI-naïve ROS1+ NSCLC ii. EXP-2: 1 Prior ROS1 TKI and 1 Platinum based
             chemo ROS1+ NSCLC iii. EXP-3: 2 Prior ROS1 TKIs and 1 Platinum based chemo ROS1+ NSCLC
             iv. EXP-4: 1 Prior ROS1 TKI ROS1+ NSCLC (No Chemo or IO) v. EXP-5: TRK TKI-naïve NTRK+
             solid tumors vi. EXP-6: TRK TKI-pretreated NTRK+ solid tumors

          8. Subjects with asymptomatic CNS metastases (treated or untreated) and/or asymptomatic
             leptomeningeal carcinomatosis are eligible to enroll if they satisfy the protocol
             specified criteria.

          9. Baseline laboratory values fulfilling the following requirements:Absolute neutrophils
             count (ANC) ≥1500/mm3 (1.5 × 109/L); Platelets (PLTs) ≥100,000/mm3 (100 × 109/L);
             Hemoglobin ≥ 9.0 g/dL transfusions are allowed; Serum creatinine or creatinine
             clearance Within normal limits or &gt; 40 mL/min; Total serum bilirubin &lt; 1.5 × ULN;
             Liver transaminases (ASTs/ALTs) &lt; 2.5 × ULN; &lt; 5 × ULN if liver metastases are present
             Alkaline phosphatase (ALP); &lt; 2.5 × ULN; &lt; 5 × ULN if liver and/or bone metastasis are
             present; Serum calcium, magnesium, and potassium Normal or CTCAE grade ≤ 1 with or
             without supplementation

         10. Life expectancy ≥ 3 months.

        Key Exclusion Criteria PHASE 1 and PHASE 2

          1. Concurrent participation in another therapeutic clinical trial.

          2. Symptomatic brain metastases or leptomeningeal involvement.

          3. History of previous cancer, except for squamous cell or basal-cell carcinoma of the
             skin, or any in situ carcinoma that has been completely resected, requiring therapy
             within the previous 2 years.

          4. Major surgery within 4 weeks of start of repotrectinib treatment. Radiation therapy
             (except palliative to relieve bone pain) within 2 weeks of study entry. Palliative
             radiation (≤10 fractions) must have been completed at least 48 hours prior to study
             entry

          5. Clinically significant cardiovascular disease (either active or within 6 months prior
             to enrollment): myocardial infarction, unstable angina, coronary/peripheral artery
             bypass graft, symptomatic congestive heart failure (New York Heart Association
             Classification Class ≥ II), cerebrovascular accident or transient ischemic attack,
             symptomatic bradycardia, requirement for anti-arrhythmic medication. Ongoing cardiac
             dysrhythmias of NCI CTCAE grade ≥2

          6. Any of the following cardiac criteria:

             Mean resting corrected QT interval (ECG interval measured from the onset of the QRS
             complex to the end of the T wave) for heart rate (QTcF) &gt; 470 msec obtained from 3
             ECGs, using the screening clinic ECG machine-derived QTc value Any clinically
             important abnormalities in rhythm, conduction or morphology of resting ECG (e.g.,
             complete left bundle branch block, third degree heart block, second degree heart
             block, PR interval &gt; 250 msec) Any factors that increase the risk of QTc prolongation
             or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT
             syndrome, family history of long QT syndrome, or any concomitant medication known to
             prolong the QT interval.

          7. Known active infections (bacterial, fungal, viral including HIV positivity).

          8. Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut
             syndrome) or other malabsorption syndromes that would impact drug absorption.

          9. Peripheral neuropathy of CTCAE ≥grade 2.

         10. History of extensive, disseminated, bilateral, or presence of CTCAE grade 3 or 4
             interstitial fibrosis or interstitial lung disease including a history of pneumonitis,
             hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease,
             obliterative bronchiolitis, and pulmonary fibrosis. Subjects with history of prior
             radiation pneumonitis are not excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shanna Stopatschinskaja, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Turning Point Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shanna Stopatschinskaja, M.D.</last_name>
    <phone>(858) 276-0005</phone>
    <email>clinical@tptherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope PHASE 2</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marianna Koczywas, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Adventist Health Glendale PHASE 2</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mihran Shirinian, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pacific Shores Oncology PHASE 2</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nishan Tchekmedyian, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Irvine Health, Chao Family Comprehensive Cancer Center PHASE 1 (recruiting) &amp; PHASE 2 (recruiting)</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Viola Zhu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center PHASE 2</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lyudmila Bazhenova, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Joseph's Heritage Healthcare PHASE 2</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ian Anderson, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver PHASE 1 (recruiting) &amp; PHASE 2 (recruiting)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Robert Doebele, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown Lombardi Comprehensive Cancer Center PHASE 2</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephen Liu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Kimmel Cancer Center PHASE 2</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Benjamin Levy, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Healthcare System PHASE 2</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Luis Raez, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center PHASE 2</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Benjamin Creelan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbus Regional Research Institute PHASE 2</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrew Pippas, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago PHASE 2</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ardman Shergill, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine PHASE 2</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christian Rolfo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital PHASE 1 (recruiting) &amp; PHASE 2 (recruiting)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jessica Lin, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Rogel Cancer Center PHASE 2</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shirish Gadgeel, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute PHASE 2</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Misako Nagasaka, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regions Hospital Cancer Care Center PHASE 2</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Arkadiusz Dudek, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University Siteman Cancer Center PHASE 2</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Haeseong Park, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute PHASE 2</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Scott Moerdler, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Health PHASE 2</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vamsidhar Velcheti, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center PHASE 1 (recruiting) &amp; PHASE 2 (Recruiting)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alexander Drilon, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center PHASE 2</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nashat Gabrail, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic PHASE 2</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Peter Anderson, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State Wexner Medical Center PHASE 2</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dwight Owen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Toledo PHASE 2</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John Nemunaitis, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center PHASE 2</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jessica Bauman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center PHASE 2</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Muhammad Beg, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Consultants P.A. PHASE 2</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Julio Peguero, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists PHASE 2</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alex Spria, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UW Seattle Cancer Care Alliance PHASE 2</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christina Baik, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Chris O-Brien Lifehouse PHASE 2</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Steven Kao, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre PHASE 2</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christos Karapetis, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Center PHASE 2</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3501</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ben Solomon, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute PHASE 2</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Quincy Chu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>William Osler Health System PHASE 2</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6R 37R</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Parneet Cheema, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital PHASE 2</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paul Wheatley-Price, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Center at University Health Network PHASE 2</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Geoffrey Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy PHASE 2</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Benjamin Besse, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital PHASE 2</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>James Ho, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital PHASE 2</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas Yau, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital PHASE 2</name>
      <address>
        <city>Sha Tin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Herbert Loong, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale Dei Tumori PHASE 2</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marina Garassino, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chungbuk National University Hospital PHASE 2</name>
      <address>
        <city>Cheongju-si</city>
        <state>Chungcheongbuk-do</state>
        <zip>28644</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ki Hyeong Lee, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital PHASE 2</name>
      <address>
        <city>Hwasun</city>
        <state>Jeollanam-do</state>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Young-Chul Kim, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital PHASE 2</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dong-Wan Kim, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center PHASE 2</name>
      <address>
        <city>Seoul</city>
        <zip>05030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kye-Young Lee, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center PHASE 2</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sang-We Kim, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center PHASE 2</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jung Yong Hong, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital PHASE 1 (recruiting) and PHASE 2 (not yet recruiting)</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dong-Wan Kim, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yonsei Cancer Center, Severance Hospital PHASE 1 (recruiting) &amp; PHASE 2 (recruiting)</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Byoung Chul Cho, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center PHASE 1</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jeeyun Lee, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Netherlands Cancer Institute PHASE 2</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Joop de Langen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universiair Medisch Centrum Groningen PHASE 2</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anthonie Van der Wekken, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne Klinika Onkologii i Radioterapii PHASE 2</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rafal Dziadziuszko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Katedra i Klinika Pneumonologii, Onkologii i Alergologii Uniwersytetu Medycznego w Lublinie PHASE 2</name>
      <address>
        <city>Lublin</city>
        <zip>20-609</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pawel Krawczyk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Med Polonia, ul. Obornicka PHASE 2</name>
      <address>
        <city>Poznan</city>
        <zip>60693</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rodryg Ramlau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Dom Lekarski PHASE 2</name>
      <address>
        <city>Szczecin</city>
        <zip>70784</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Piotr Serwatowski, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National University Hospital PHASE 2</name>
      <address>
        <city>Singapore</city>
        <state>Central Singapore</state>
        <zip>119704</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ross Soo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Singapore PHASE 2</name>
      <address>
        <city>Singapore</city>
        <state>Central Singapore</state>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Darren Lim, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra PHASE 2</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ignacio Gil-Bazo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron University Hospital PHASE 2</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Enriqueta Felip, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundacion MD Anderson PHASE 2</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Enrique Grande, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>START Madrid-FJD PHASE 2</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Victor Moreno, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre PHASE 2</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Luis Paz-Ares, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología PHASE 2</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Angel Guerrero, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust PHASE 2</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sanjay Popat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imperial College London - Hammersmith Hospital PHASE 2</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Pinato, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute PHASE 2</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anna Patrikidou, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust PHASE 2</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Matthew Krebs, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 6, 2017</study_first_submitted>
  <study_first_submitted_qc>March 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2017</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALK</keyword>
  <keyword>ROS1</keyword>
  <keyword>NTRK</keyword>
  <keyword>Sarcoma</keyword>
  <keyword>Lung Neoplasms</keyword>
  <keyword>Carcinoma, NSCL</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Non Small Cell Lung</keyword>
  <keyword>Thyroid Disease</keyword>
  <keyword>Colonic Neoplasms</keyword>
  <keyword>Thyroid Neoplasms</keyword>
  <keyword>Carcinoma, Neuroendocrine</keyword>
  <keyword>Respiratory Tract Neoplasms</keyword>
  <keyword>Thoracic Neoplasms</keyword>
  <keyword>Neoplasms by Site</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Lung Disease</keyword>
  <keyword>Respiratory Tract Disease</keyword>
  <keyword>Carcinoma, Bronchogenic</keyword>
  <keyword>Bronchial Neoplasms</keyword>
  <keyword>Endocrine System Disease</keyword>
  <keyword>Colorectol Neoplasms</keyword>
  <keyword>Intestinal Neoplasms</keyword>
  <keyword>Gastrointestinal Neoplasms</keyword>
  <keyword>Digestive System Neoplasms</keyword>
  <keyword>Gastrointestinal Disease</keyword>
  <keyword>Colonic Disease</keyword>
  <keyword>Intestinal Disease</keyword>
  <keyword>Endocrine Gland Neoplasms</keyword>
  <keyword>Head and Neck Neoplasms</keyword>
  <keyword>Neuroendocrine Tumors</keyword>
  <keyword>Neuroectodermal Tumors</keyword>
  <keyword>Neoplasms, Germ Cell and Embryonal</keyword>
  <keyword>Neoplasms by Histologic Type</keyword>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Non Small Cell Lung Cancer</keyword>
  <keyword>Solid Tumors</keyword>
  <keyword>Rearrangements</keyword>
  <keyword>TRIDENT-1</keyword>
  <keyword>TKI</keyword>
  <keyword>TKI naive</keyword>
  <keyword>TKI pretreated</keyword>
  <keyword>Anti-tumor activity</keyword>
  <keyword>Repotrectinib</keyword>
  <keyword>Advanced Solid Malignancies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There are no plans to share individual participant data with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

